O ver the last decade, the application of genetics to cardiac risk has transitioned from single gene assessment in rare mendelian disorders to more common complex phenotypes such as ischemic heart disease, atrial fibrillation, and heart failure. This transition has been accelerated by the advances in genomic technology that have made Genome Wide Association Studies (GWAS) both practical and productive. In any clinical research, study number is power, and nowhere is that more important than GWAS, in which the cost of millions of simultaneous single nucleotide polymorphism (SNP) assessments is the need to set the statistical level of significance sufficiently low to avoid false-positives. This need for larger GWAS cohorts has led investigators to develop "networks of networks" to identify novel loci that are ultimately reproducible and truly important to cardiovascular risk and/or outcomes. In this issue of Circulation: Cardiovascular Genetics, the CHARGE investigators have used such a strategy and present meta-analyses of 4 community-based cohorts to evaluate genomic heart failure risk 1 and heart failure mortality 2 in nearly 24 000 subjects. Their findings demonstrate both the promise and the challenges of applying GWAS to heart failure.
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Patients with similar myocardial insults progress to the heart failure syndrome at markedly variable rates and degrees, and in the modern era it is clear that a significant portion of this clinical heterogeneity is genetically based. Indeed, analysis from multigenerational cohorts from the Framingham study has estimated that 28% of the risk of heart failure caused by systolic dysfunction can be attributed to genetic factors. 3 Given the well-described pathways of heart failure pathogenesis, it seems logical to start the assessment of individual "genomic" risks of heart failure with SNPs or common deletion/insertions that affect neurohormonal activation. As early as 1993, investigators from the University of Colorado reported an increased prevalence of the ACE DD genotype in heart transplant recipients compared with control subjects, 4 and soon afterward investigations of a Swedish cohort with "idiopathic heart failure" suggested that both the ACE D allele 5 and ␤ 1 receptor variants 6 were associated with worse heart failure survival. These initial reports led to pharmacogenetic investigations in heart failure by our group 7 and others. 8 Although the targeted hypothesis driven by single gene investigations appeared promising, they were limited by subject number and in many cases led to findings that were not reproducible. 9 Indeed, more than 15 years after the first reports of the ACE D allele affecting risk and prognosis in heart failure, no single genetic test has yet been applied to the clinical management of this complex disorder.
Given the complexity of the heart failure syndrome, it is perhaps not surprising that single gene variants have fallen short in terms of clinical application, and the need for a more comprehensive genomic approach has been increasingly emphasized. Over the last decade, the success of GWAS in defining new disease-associated loci 10, 11 in a reproducible fashion has given credence to the belief that a genome-wide approach is preferable for investigating common polygenic disorders. With appropriately sized and well-phenotyped cohorts, GWAS has the capability for determining all major genetic loci linked to a specific cardiovascular risk and, in the process, identifying novel genes involved in pathogenesis whose impact had not previously been recognized. Performing this analysis requires large, well-phenotyped cohort, and in this regard the CHARGE consortium delivers a welldescribed heart failure cohort with careful follow-up that exceeds any previously studied.
The CHARGE consortium consists of 4 community-based prospective cohorts: the Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), and the Rotterdam Study (RS). The investigators from CHARGE 1 performed a metaanalysis of GWAS from nearly 21 000 subjects of European ancestry and almost 3000 subjects of African ancestry. The primary end point was the incidence of heart failure events based on self-reports and confirmed by hospital records. Genome-wide assays of SNPs were performed independently for the 4 cohorts and resulted in an examination of nearly 2.5 million SNPs. The risk assessment for the subset of subjects of European ancestry and African ancestry were analyzed separately (only ARIC and CHS cohorts contained black subjects). This approach of separate analysis for ethnic cohorts is necessary, given the marked differences in minor allele frequencies between black and white cohorts as well as the differences in linkage disequilibrium which limit mapping capabilities in cohorts of African ancestry.
The assessment of heart failure risk only identified a single locus in each ethnic cohort at the prespecified genome wide significance of 5ϫ10 Ϫ7 . In the European subset the locus was at 15q22 near USP3, ubiquitin-specific peptidase 3, with a hazard ratio of 1.53 for the adverse allele. In the African ancestry subset, a separate locus associated with heart failure risk was found at 12q14 with a similar hazard ratio. In addition, in both ethnic subsets a number of "high signal" SNPs were identified that had probability values of Ͻ10 Ϫ5 but did not reach the prespecified significance level. However, there was no concordance between the findings in the black and white cohorts. The adverse alleles identified in the white subset were not significant in the black cohort and in fact showed no elevation of the hazard ratio. In a similar fashion, the adverse alleles identified in blacks were not significant and showed no elevation of the hazard ratio in whites.
The second report from the CHARGE consortium 2 takes the heart failure genomic analysis a step further and investigates the risk of death among those identified as heart failure subjects. This limits the total study number to those in the previous paper ultimately determined to have heart failure and asks which loci predicts mortality within the heart failure cohort. This analysis reveals a genomic locus in the European cohort on chromosome 3p22 in the intron of a CKLF-like MARVEL transmembrane domain containing 7 (CMTM7). No locus reached genome-wide significance for the group of African ancestry. As with the first analysis, multiple "high signal" SNPs were identified, but there was again little concordance between the findings in the subset of European with that seen in the subset of African ancestry.
This meta-analysis of the CHARGE was uniquely positioned to investigate heart failure risk and mortality in a manner not previously possible, and the investigators are to be congratulated on a well-designed and executed study whose identification of several novel gene loci is of significant interest. The authors point out that given the number of markers evaluated (roughly 2.5 million per subject), finding 1 positive locus per cohort is about what one would expect by chance. The 3 significant novel loci identified (and potentially the other "high signal SNPs" of interest) should be reinvestigated in similar additional cohorts. The uniqueness of the large CHARGE consortium, a well-phenotyped population that was followed for decades, represents a challenge for future validation. Development of similarly large heart failure cohorts will require recruitment and follow-up of end points (such as the development of heart failure and outcomes including mortality) that necessitate many years of prospective follow-up.
The heart failure phenotype may differ between distinct ethnic cohorts. Hypertension is a more common etiology of heart failure in blacks, whereas coronary disease is more common in whites. In addition, the overall response to medical therapeutics differs between black and white heart failure cohorts. 12 It is possible that the lack of concordance between the 2 ethnic cohorts in CHARGE represents true differences in genetic background and risk assessment. However, the apparent lack of concordance between these 2 ethnic cohorts in CHARGE may more simply reflect the limitation of the genomic analyses used in the cohorts of African ancestry. Although it is possible that the genetic risk of heart failure may differ in subjects of African versus European ancestry, some similarities of genomic drivers would be anticipated pathologically and the technological limitations and lower number of subjects in the African ancestry subset make true comparison across ethnic subsets more challenging. Additional studies specifically in black heart failure cohorts may help to clarify this important issue.
How one looks at the heart failure GWAS data presented by the CHARGE consortium depends on whether one wants to look at our "genomics glass" as half full or half empty. The statistical bar necessitated by the large numbers of markers used biases the results against all but the most common SNPs with a fairly robust increase in risk. Although we agree with the authors that it is important to try and replicate the results for the 3 significant genomic loci, many of the "high signal" SNPs that failed to reach genomic significance in CHARGE may prove themselves in future cohorts to be of greater significance than can be concluded from this single analysis.
The meta-analysis presented has the limitations inherent when combining several distinct genetic outcomes studies including differences in cohort make up, end point determination, and genetic maps used. Despite these limitations, there is tremendous information to be gained by large-scale collaborative GWAS studies such as the one presented here, powered to evaluate both heart failure risk and outcomes. We hope that this is only the first of many studies applying GWAS in appropriately sized heart failure cohorts. These future studies may confirm the loci identified here and will eventually determine the location of the important genomic drivers that underlie the 28% of heart failure risk defined as heritable. When coupled with improvements in polygenic risk assessment, GWAS has the potential to assist the development of genomics as a clinical tool to assist not only in risk determination but in prognostic assessment.
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